Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing pressure will increase over time in emerging markets, hitting the bottom line of multinationals, particularly those with high exposure to branded generics, Deutsche Bank predicts.